Your browser doesn't support javascript.
loading
Molecular determinants of immunogenic cell death elicited by radiation therapy.
Galassi, Claudia; Klapp, Vanessa; Yamazaki, Takahiro; Galluzzi, Lorenzo.
Afiliação
  • Galassi C; Department of Radiation Oncology, Weill Cornell Medical College, New York, New York, USA.
  • Klapp V; Tumor Stroma Interactions, Department of Cancer Research, Luxembourg Institute of Health, Luxembourg, Luxembourg.
  • Yamazaki T; Faculty of Science, Technology and Medicine, University of Luxembourg, Esch-sur-Alzette, Luxembourg.
  • Galluzzi L; Department of Radiation Oncology, Weill Cornell Medical College, New York, New York, USA.
Immunol Rev ; 321(1): 20-32, 2024 Jan.
Article em En | MEDLINE | ID: mdl-37679959
Cancer cells undergoing immunogenic cell death (ICD) can initiate adaptive immune responses against dead cell-associated antigens, provided that (1) said antigens are not perfectly covered by central tolerance (antigenicity), (2) cell death occurs along with the emission of immunostimulatory cytokines and damage-associated molecular patterns (DAMPs) that actively engage immune effector mechanisms (adjuvanticity), and (3) the microenvironment of dying cells is permissive for the initiation of adaptive immunity. Finally, ICD-driven immune responses can only operate and exert cytotoxic effector functions if the microenvironment of target cancer cells enables immune cell infiltration and activity. Multiple forms of radiation, including non-ionizing (ultraviolet) and ionizing radiation, elicit bona fide ICD as they increase both the antigenicity and adjuvanticity of dying cancer cells. Here, we review the molecular determinants of ICD as elicited by radiation as we critically discuss strategies to reinforce the immunogenicity of cancer cells succumbing to clinically available radiation strategies.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Immunol Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias / Antineoplásicos Limite: Humans Idioma: En Revista: Immunol Rev Ano de publicação: 2024 Tipo de documento: Article País de afiliação: Estados Unidos